Tempus AI, a genetic testing firm backed by SoftBank Group, has received bullish coverage from multiple Wall Street analysts. Needham initiated coverage with a Buy rating and a price target of $47, citing the company's differentiated, AI-powered approach to precision medicine and its extensive 200-petabyte multimodal dataset. Bank of America also initiated coverage with a Buy rating and a $41 price target, highlighting the premium valuation as well-warranted. TD Cowen joined the bullish sentiment by initiating coverage with a Buy rating as well. Analysts believe that Tempus AI's comprehensive library of clinical and molecular data could significantly enhance oncologists' ability to provide better patient care and aid life sciences companies in developing more effective treatments.